Among the most-read stories in endocrinology this week was the announcement that the FDA suspended the trial of an investigational drug for treating type 2 diabetes and that the federal agency had issued two draft guidances for blood glucose meters.
Other popular stories included a position statement from two endocrinology societies that identified multiple stages of type 2 diabetes, a study that provided potential warning signs of Addison’s disease in patients with type 1 diabetes, and an analysis that showed dehydroepiandrosterone therapy may preserve bone muscle mass in older women. – by Janel Miller
FDA suspends clinical trial for investigational diabetes drug
The FDA placed a clinical hold on an investigational new drug application for a second-generation MetAP2 inhibitor in development for the treatment of type 2 diabetes, citing cardiovascular safety concerns, Zafgen announced in a press release. Read more.
FDA issues 2 revised draft guidances for blood glucose meters
The FDA recently issued two revised draft guidances for blood glucose monitors in home and health care settings, following a request from stakeholders for more clarification on design considerations and recommended standards for meters, according to a press release from the agency. Read more.
Position statement identifies 4 distinct stages of type 2 diabetes
A new complications-centric model identifies four distinct, evidence-based disease stages along the type 2 diabetes spectrum, emphasizing preventive care that begins at the first signs of insulin resistance, according to a joint position statement from the American Association of Clinical Endocrinologists and the American College of Endocrinology. Read more.
Autoimmune thyroid disease, retinopathy may signal Addison’s disease in type 1 diabetes
Medical treatment for autoimmune thyroid disease, an infection requiring hospitalization or the development of retinopathy should “raise the suspicion” of Addison’s disease development in adults with type 1 diabetes, according to findings from a registry-based study conducted in Sweden. Read more.
Dehydroepiandrosterone therapy may preserve bone muscle mass in older women
Among older women, the adrenal steroid dehydroepiandrosterone may attenuate declines in bone mineral density and modestly increase fat-free mass over 12 months when compared with placebo, according to findings from a pooled analysis published in Clinical Endocrinology. Read more.